Effects of neoadjuvant chemotherapy on pathological parameters and survival in patients undergoing radical cystectomy for muscle-invasive bladder cancer

Aim: To evaluate the effect of neoadjuvant chemotherapy on tumor pathology and patient survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Neoadjuvant chemotherapy is believed to prevent micrometastasis and provide pathological downstaging. Materials and methods: Between June 2004 and March 2009, 74 patients with muscle-invasive bladder cancer were treated with radical cystectomy. Patients fit to receive chemotherapy were administered systemic chemotherapy of methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC); gemcitabine and cisplatin (GC); or carboplatin and gemcitabine (CG). Patients in Group 1 (n = 36) did not receive any chemotherapy, while the remaining 38 patients in Group 2 did so, before radical cystectomy. Patient characteristics, pathological staging, and survival analysis were compared statistically between groups. Results: The mean follow-up time was 16.12 ± 12.13 months. There was no significant difference between the groups regarding patient age, sex, preoperative clinical staging, lymph node invasion, comorbidity, type of urinary diversions done, postoperative early complications, progression-free survival (21.96 ± 3.5 and 23.44 ± 2.5 months; P = 0.275), and overall survival rates (25.76 ± 3.5 and 23.57 ± 2.4 months; P = 0.646). However, differences in pathological downstaging (pT3-pT4, 21.58% and 16.42% for groups 1 and 2, respectively; P < 0.001) and perioperative mortality (6 vs. 0 deaths in groups 1 and 2; respectively) were significant between groups. Conclusion: Neoadjuvant chemotherapy may result in pathological downstaging while having no effects on progression-free or overall survival rates.

Effects of neoadjuvant chemotherapy on pathological parameters and survival in patients undergoing radical cystectomy for muscle-invasive bladder cancer

Aim: To evaluate the effect of neoadjuvant chemotherapy on tumor pathology and patient survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Neoadjuvant chemotherapy is believed to prevent micrometastasis and provide pathological downstaging. Materials and methods: Between June 2004 and March 2009, 74 patients with muscle-invasive bladder cancer were treated with radical cystectomy. Patients fit to receive chemotherapy were administered systemic chemotherapy of methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC); gemcitabine and cisplatin (GC); or carboplatin and gemcitabine (CG). Patients in Group 1 (n = 36) did not receive any chemotherapy, while the remaining 38 patients in Group 2 did so, before radical cystectomy. Patient characteristics, pathological staging, and survival analysis were compared statistically between groups. Results: The mean follow-up time was 16.12 ± 12.13 months. There was no significant difference between the groups regarding patient age, sex, preoperative clinical staging, lymph node invasion, comorbidity, type of urinary diversions done, postoperative early complications, progression-free survival (21.96 ± 3.5 and 23.44 ± 2.5 months; P = 0.275), and overall survival rates (25.76 ± 3.5 and 23.57 ± 2.4 months; P = 0.646). However, differences in pathological downstaging (pT3-pT4, 21.58% and 16.42% for groups 1 and 2, respectively; P < 0.001) and perioperative mortality (6 vs. 0 deaths in groups 1 and 2; respectively) were significant between groups. Conclusion: Neoadjuvant chemotherapy may result in pathological downstaging while having no effects on progression-free or overall survival rates.

___

  • Greenlee RT, Murray T, Bolden S, Wings PA. Cancer statistics. CA Cancer J Clin 2000; 50: 7.
  • Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2009; 55: 348-58.
  • Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 608-15.
  • Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or defi nitive radiation. Th e National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901-7.
  • Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, Flores N, Roncero CR, Portillo JA et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995; 153: 964-73.
  • Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year follow up at a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial. Th e Nordic Cooperative Bladder Cancer Study Group. J Urol 1996; 155: 1903-6.
  • Ghoneim MA, Abol-Enein H. Management of muscle-invasive bladder cancer. Nat Clin Pract Urol 2008; 5: 501-8.
  • Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF et al. Surgical factors infl uence bladder cancer outcome: a cooperative group report. J Clin Oncol 2004; 22: 2781-9.
  • McLaren DB. Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder. Clin Oncol 2005; 17: 503-7.
  • Black PC, Brown GA, Grossman HB, Dinney CP. Neoadjuvant chemotherapy for bladder cancer. World J Urol 2006; 24: 531- 42.
  • Sawhney R, Bourgeois D, Chaudhary UB. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead. Ann Oncol 2006; 17: 1360-9.
  • Kulkarni GS, Urbach DR, Austin PC, Laupacis A. Longer wait times increase overall mortality in patients with bladder cancer. J Urol 2009; 182: 1318-24.
  • Smaldone MC, Corcoran AT, Hayn M, Konety BR, Hrebinko RL Jr, Davies BJ. Estimating postoperative mortality and morbidity risk of radical cystectomy with continent diversion using predictor equations. J Urol 2009; 182: 2619-24.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Sayıdaki Diğer Makaleler

Assessment of exposure to tobacco smoke: measurement of exhaled carbon monoxide and hair nicotine

İbrahim DEMİRTAŞ, Hüseyin AKŞİT, Sibel DORUK, Zehra SEYFİKLİ, Ünal ERKORKMAZ

Do the applied shock wave numbers and the application side aff ect pancreatic exocrine functions in patients who have undergone extracorporeal shock wave lithotripsy for upper urinary tract calculi?

Ercan YENİ, Hakim ÇELİK, Halil ÇİFTÇİ, Mehmet GÜLÜM, Murat SAVAŞ

Cytotoxic effect of cigarette smoke condensate on mice and rat mesenchymal stem cells and HeLa cells

Aftab AHMAD, Abdul Rauf SHAKOORI

A combination therapy of half-dose verteporfin photodynamic therapy and intravitreal injection of ranibizumab for chronic central serous chorioretinopathy

Yasin TOKLU, Hasan Basri ÇAKMAK, Mücella Arikan YORGUN, Şule Berk ERGUN, Şaban ŞİMŞEK

Iodine deficiency in pregnancy and in women of reproductive age in Erzurum, Turkey

Metin İNGEÇ, Semra ÇETİNKAYA, Kadir ÇETİNKAYA, İbrahim KAPLAN

The effect of N-acetylcysteine on growth and biofi lm formation in Staphylococcus epidermidis strains

Sahra KIRMUSAOĞLU, Seyhun YURDUGÜL, M. Esra KOÇOĞLU

The effects of the Cobra perilaryngeal airway on intraocular pressure

Lale KARABIYIK, Sema ÖNCÜL, Gökçen EMMEZ

Bother index can be used in deciding how the symptom nocturia itself is important

Hacı İbrahim ÇİMEN, Ahmet Tunç ÖZDEMİR, Ege Can ŞEREFOĞLU, Ali Fuat ATMACA, Serkan ALTINOVA, Mevlana Derya BALBAY

Contribution of phospholipase C and protein kinase C but not endothelin-converting enzyme to contractile responses of ethanol

Naciye DÖNDAŞ, Derya KAYA, Erğin ŞİNGİRİK, Halil Mahir KAPLAN

Comparison of anesthesia with sevofl urane-N2O and midazolam-remifentanil in low-birth-weight premature infants undergoing diode laser photocoagulation

Levent ÖZTÜRK, Eyüp HORASANLI, Abdulkadir BUT, Müge ARIKAN, Meltem TABUK, Bilge ASLAN